The ‘Angelina effect’

LONDON: Two years after Hollywood actress Angelina Jolie went public about having a gene mutation linked to breast cancer and her preventative double mastectomy, a new UK study has shown that the number of preventative operations of this kind has risen.

Jolie’s announcement in May 2013 that she had had a double mastectomy caused a media storm. The American actress carries a mutation in the BRCA1 gene, as did her mother, who died of breast cancer. She explained that she decided to have the operation to eliminate the 87 per cent risk that she would one day develop breast cancer.

Her decision led to renewed interest in breast cancer genetic research which a research team at a breast cancer prevention clinic at the University Hospital of South Manchester in the UK decided to investigate. The researchers noted, the number of double mastectomies carried out in their clinic had more than doubled between January 2014 and June 2015, reaching a total of 83 procedures, whereas only 29 preventive mastectomies had been performed there between January 2011 and June 2012.

Professor of clinical genetics Gareth Evans and his team believe that the “Angelina Jolie effect” did much to encourage them.

The researchers noted there was even an increase in the number of procedures on high-risk women without the BRCA1/2 gene mutation (up from 12 to 52 over the same period).